MONDAY, MAY 1
Arrival and Registration

TUESDAY, MAY 2
Welcome and Keynote Address

Robert E. Ratner, Georgetown University School of Medicine and Virta, USA
T2D - Beginning to End and a Need to Better Treat It

Detecting T2D Early and Predicting its Progress - A Precision Approach

William Cefalu, NIDDK, National Institutes of Health, USA
Prediabetes – Prevalence, Early Detection and Precision Treatment for Better Outcomes

Jose C. Florez, Massachusetts General Hospital, USA
Segmenting Type 2 Diabetes

Ruth J.F. Loos, University of Copenhagen, Denmark
Did We Learn Anything from T2D GWAS

Short Talk(s) Chosen from Abstracts

Workshop 1: Precision Medicine for (Pre)Diabetes

Short Talks Chosen from Abstracts

Drivers of T2D Disease Progression

Meredith A. Hawkins, Albert Einstein College Of Medicine, USA
Nutrition Deficiency and Nutrient Excess

James Trevaskis, Eli Lilly, USA
Fatty Liver Disease, Fibrosis and Diabetes

Rebecca Anne Simmons, University of Pennsylvania School of Medicine, USA
Intra-Uterine Programming

Short Talk(s) Chosen from Abstracts

Poster Session 1

WEDNESDAY, MAY 3
Insulin Resistance to Beta Cell Failure

Justin J. Rochford, University of Aberdeen, UK
T2D Associated with Leanness and Lipodystrophy

Gerald I. Shulman, Yale University School of Medicine, USA
Mechanisms of Obese Insulin Resistance – Metabolism and Pathophysiology

Christopher J. Rhodes, AstraZeneca, USA
Beta Cell Rest and Rejuvenation

Short Talk(s) Chosen from Abstracts

Targeting CNS, Gut and Adipose Tissue in T2D Therapy

Tune H. Pers, University of Copenhagen, Denmark
Bioinformatics to Unravel CNS Circuitries

Martin G. Myers, Jr., University of Michigan, USA
Brain – Metabolism Axis in T2D

Short Talk(s) Chosen from Abstracts

THURSDAY, MAY 4
Reversing T2D - Alternate Means and Mechanisms

Darleen A. Sandoval, University of Colorado, USA
Mechanisms of Bariatric Surgery and Gut Peptide Therapeutics

Juleen R. Zierath, Karolinska Institutet, Sweden
Energy Expenditure and Exercise

Jared Rutter, University of Utah - Biochemistry, USA
Mitochondrial (Dys)function

Karine Clément, INSERM / Sorbonne Universite, France
Microbiome

Short Talk(s) Chosen from Abstracts

Workshop 2: Incretin Action – Beyond the beta-Cell

Short Talks Chosen from Abstracts

T2D Therapeutics - Current and Emerging

Kevin L. Grove, Novo Nordisk, USA
Treating Obesity to Treat T2D

Anish Konkar, Eli Lilly and Company, Germany
Utility of GLP-1-Based Mono, Dual and Triagonists for the Treatment of T2D and Related Comorbidities

Ben Challis, AstraZeneca, UK
Future Therapeutics - Reverse T2D and Resolve Complications

Short Talk Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, MAY 5
Departure

* Session Chair † Invited but not yet accepted     Program current as of November 17, 2022 Meal formats are based on meeting venue.
For the most up-to-date details, visit https://www.keystonesymposia.org.